On an expansion tear, Eli Lilly reveals $1.8B in investments at Irish manufacturing sites
Eli Lilly has again upped the ante in scaling up its manufacturing footprint, this time revealing an investment totaling $1.8 billion to expand production capacity at two plants in Ireland. | Eli Lilly has again upped the ante in scaling up its manufacturing footprint,
Eli Lilly invests $1.8 bln in Ireland sites to scale up Alzheimer's, obesity drug production
Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said on Thursday.
Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...
HealthDay on MSN3h
Alzheimer's Drugs May Work in Whole New Way, Study FindsTwo monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...
In a new survey, 56% of respondents said they plan to get a flu shot this fall, while just 43% said they'll get an updated ...
The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...
A Hartsville hospital patient is among the first in the United States to receive a new treatment that helps slow the ...
Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of ...
Kisunla (donanemab-azbt) is a brand-name injection for IV infusion that’s prescribed for certain types of Alzheimer’s disease in adults. As with other drugs, Kisunla can cause side effects ...
Kisunla (donanemab-azbt) is a prescription drug that’s used to treat Alzheimer’s disease in adults. This drug currently isn’t known to interact with other drugs. Note: As a person’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback